Effect of prasugrel in patients with asthma: Results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 1, 2015, Pages 136-141

  Lussana, F ^a,b   Di Marco, F ^a   Terraneo, S ^a   Parati, M ^a   Razzari, C ^a   Scavone, M ^a   Femia, E A ^a   Moro, A ^a   Centanni, S ^a   Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

Asthma; Blood platelets; Inflammation; Prasugrel; Thienopyridines

Indexed keywords

MANNITOL; NITRIC OXIDE; PLACEBO; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BREATH ANALYSIS; BRONCHIAL HYPERREACTIVITY; BRONCHOCONSTRICTION; DRUG EFFECTS; INHALATION TEST; ITALY; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BREATH TESTS; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; ITALY; LUNG; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TREATMENT OUTCOME;

EID: 84920982440     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12779     Document Type: Article

References (29)

1. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-74.
2. Amison R, Page C, Pitchford S. Pharmacological modulation of the inflammatory actions of platelets. Handb Exp Pharmacol 2012; 210: 447-68.
3. Ware J, Corken A, Khetpal R. Platelet function beyond hemostasis and thrombosis. Curr Opin Hematol 2013; 20: 451-6.
4. Knauer KA, Fish JE, Adkinson NF Jr, Lichtenstein LM, Peters SP, Newball HH. Platelet activation in antigen-induced bronchoconstriction. N Engl J Med 1981; 305: 892-3.
5. Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, Giannini S, Momi S, Spina D, O'Connor B, Gresele P, Page CP. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003; 112: 109-18.
6. Pitchford SC, Riffo-Vasquez Y, Sousa A, Momi S, Gresele P, Spina D, Page CP. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood 2004; 103: 639-47.
7. Pitchford SC, Momi S, Baglioni S, Casali L, Giannini S, Rossi R, Page CP, Gresele P. Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med 2008; 177: 604-12.
8. Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 2012; 42: 1313-20.
9. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-6.
10. Hui Y, Yang G, Galczenski H, Figueroa DJ, Austin CP, Copeland NG, Gilbert DJ, Jenkins NA, Funk CD. The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 2001; 276: 47489-95.
11. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-6.
12. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013; 288: 10967-72.
13. Hasegawa S, Ichiyama T, Hashimoto K, Suzuki Y, Hirano R, Fukano R, Furukawa S. Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets 2010; 21: 253-9.
14. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-9.
15. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y, Kanaoka Y, Conley P, Boyce JA. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206: 2543-55.
16. Cummings HE, Liu T, Feng C, Laidlaw TM, Conley PB, Kanaoka Y, Boyce JA. Cutting edge: leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol 2013; 191: 5807-10.
17. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132: 151-8.
18. Wood LG, Powell H, Gibson PG. Mannitol challenge for assessment of airway responsiveness, airway inflammation and inflammatory phenotype in asthma. Clin Exp Allergy 2010; 40: 232-41.
19. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl 2002; 37: 3s-8s.
20. ATS/ERS. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-30.
21. Schiller B, Hammer J, Barben J, Trachsel D. Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. Pediatr Allergy Immunol 2009; 20: 679-85.
22. Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost 2012; 107: 494-506.
23. Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost 2012; 10: 327-36.
24. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, DiMaria G, Foresi A, Hargreave FE, Holgate ST, Inman M, Lotvall J, Magnussen H, Polosa R, Postma DS, Riedler J. Indirect airway challenges. Eur Respir J 2003; 21: 1050-68.
25. Cattaneo M. The platelet P2Y(1)(2) receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-12.
26. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005; 337: 281-8.
27. Cattaneo M. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost 2011; 105(Suppl. 1): S67-74.
28. Vachier I, Kumlin M, Dahlen SE, Bousquet J, Godard P, Chanez P. High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med 2003; 97: 1225-9.
29. Bunyavanich S, Boyce JA, Raby BA, Weiss ST. Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma. Clin Exp Allergy 2012; 42: 229-37.